Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Iovance Biotherapeutics Inc IOVA

Healthcare Biotechnology
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult... see more

Current News (NDAQ:IOVA)

Iovance Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire 11 days ago

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

GlobeNewswire 13 days ago

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

GlobeNewswire 13 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 20, 2026

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

GlobeNewswire February 11, 2026

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

GlobeNewswire February 5, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 16, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)

GlobeNewswire January 12, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 19, 2025
View More News ››

Opinion & Analysis (NDAQ:IOVA)

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Streetwise Reports November 12, 2019

Preliminary Phase 2 clinical data provides 'first spark to game-changing thesis'

Streetwise Reports January 31, 2018

Cell therapy for melanoma impresses in Phase 2

The Life Sciences Report August 10, 2017
View More Opinion ››

Bullboard Posts (NDAQ:IOVA)

Buy buddy buy because it's taking off this morning.

Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
coolfooldumbguy - August 19, 2025

Buy buddy buy.

Otherwise FOMO for you guys out there today anyway
coolfooldumbguy - July 25, 2025

Using technical analysis for this stock.

It looks like the bottom price per share of this stock is behind it and that's a big positive for shareholders today anyway and it...
coolfooldumbguy - July 22, 2025
View more Bullboard ››

AKITA Drilling Ltd.

AKITA Drilling Ltd.

AKITA Drilling Ltd. operates as an oil and gas drilling contractor in Canada and the United States. It is involved in the ...
View More »

Podcasts